As recently as 2011 we considered the risk of breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) to be 1 in 1 million; only 27 cases had been reported in the literature, and only 1 case-control study suggested an association, without evidence of causation, between this cancer and breast implants.1 We now recognize BIA-ALCL is a rare non-Hodgkin’s T-cell lymphoma that is associated with textured breast implants; around 800 recognized cases have been reported worldwide and the incidence appears to be increasing. As many as 87% of patients present as stage I disease due to the early onset of visible symptoms, predominantly delayed-onset peri-implant seroma.2 At this early stage the disease is indolent and curable with appropriate surgery alone with no recurrence and this has been recognized since 2011.3